Thoracic

Non Small Cell Lung Cancer (NSCLC)

Stage I-III: Unresectable

Stage I-III

Treated w/ SBRT +/- adjuvant chemo

LUN0115
Phase II Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

PI: Neal
Sponsor: Stanford University

LUN0114
Personalized Escalation of Consolidation Treatment After ChemoRT & Immunotherapy in Stage IIB/III NSCLC

PI: Neal
Sponsor: Stanford University

Stage II-III

LUN0132
Phase III Trial of Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer

PI: Vitzthum
Sponsor: Stanford University

Stage III EGFR

LUN0136
Phase II Open-Label Single-Arm Study of Osimertinib as Induction Therapy Prior to CRT & Maintenance Osimertinib in Epidermal Growth Factor Receptor (EGFR) Mutation-Positive, Stage III, Unresectable Non-Small Cell Lung Cancer (NEOLA)

PI: Wakelee
Sponsor: AstraZeneca

KEY

Pending
Open for Enrollment
Observational Study

Optional Path
Link
Trial Posting

Extension Study
Immunotherapy

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu